Evidence map›Paper›PMID 38168207›Full record

ArticlebioRxiv : the preprint server for biology2023

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines.

Jimin Lee, Cameron Stewart, Alexandra Schaefer, Elizabeth M Leaf, Young-Jun Park, Daniel Asarnow, John M Powers, Catherine Treichel, Davide Corti, Ralph Baric and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Jimin LeeDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Cameron StewartDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Alexandra SchaeferDepartment of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA.
Elizabeth M LeafDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Young-Jun ParkDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Daniel AsarnowDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
John M PowersDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Catherine TreichelDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Davide CortiHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Ralph BaricDepartment of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA.
Neil P KingDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
University of Washington · USUniversity of North Carolina at Chapel Hill · USHoward Hughes Medical Institute · USVir Biotechnology (Switzerland) · CH

Funding

Centers for Research on Structural Biology of Infectious Diseases: Universal Influenza Vaccine Research75N93022C00036 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART · 2022 to 2025
$21.7M
Structure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI Francois J Villinger · 2022 to 2026
$15.3M
Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4M
NIAID NIH HHS 75N93022C00036NIAID NIH HHS DP1 AI158186NIAID NIH HHS P01 AI167966
6 · The paper itself

Abstract

Continuous evolution of SARS-CoV-2 alters the antigenicity of the immunodominant spike (S) receptor-binding domain and N-terminal domain, undermining the efficacy of vaccines and monoclonal antibody therapies. To overcome this challenge, we set out to develop a vaccine focusing antibody responses on the highly conserved but metastable S

Identifiers

PMID38168207
PMCPMC10760017
OpenAlexW4389765708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.